Pharming Group N.V. (PHAR)
USD 7.66
(-0.39%)
USD 7.66
(-0.39%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -10.54 Million USD | -177.14% |
| 2022 | 13.67 Million USD | -14.52% |
| 2021 | 15.99 Million EUR | -57.62% |
| 2020 | 37.74 Million EUR | -6.9% |
| 2019 | 40.54 Million EUR | 41.82% |
| 2018 | 28.58 Million EUR | 129.8% |
| 2017 | -95.92 Million EUR | -420.12% |
| 2016 | -18.44 Million EUR | -69.42% |
| 2015 | -10.88 Million EUR | -55.23% |
| 2014 | -7.01 Million EUR | 66.28% |
| 2013 | -20.79 Million EUR | 34.73% |
| 2012 | -31.86 Million EUR | -43.73% |
| 2011 | -22.16 Million EUR | 70.43% |
| 2010 | -74.96 Million EUR | -63.2% |
| 2009 | -45.93 Million EUR | -25.92% |
| 2008 | -36.47 Million EUR | 29.74% |
| 2007 | -51.92 Million EUR | -112.7% |
| 2006 | -24.41 Million EUR | -15.41% |
| 2005 | -21.15 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -12.41 Million USD | -356.21% |
| 2024 Q2 | -1.19 Million USD | 90.35% |
| 2024 Q3 | -1.03 Million USD | 13.75% |
| 2023 FY | -10.54 Million USD | -177.14% |
| 2023 Q1 | -12.2 Million USD | 16.56% |
| 2023 Q4 | -2.72 Million USD | -178.58% |
| 2023 Q2 | 1.31 Million USD | 110.8% |
| 2023 Q3 | 3.46 Million USD | 162.62% |
| 2022 Q3 | 9.1 Million USD | -42.19% |
| 2022 FY | 13.67 Million USD | -14.52% |
| 2022 Q2 | 15.74 Million USD | 354.84% |
| 2022 Q1 | 3.46 Million USD | 85.98% |
| 2022 Q4 | -14.63 Million USD | -260.75% |
| 2021 Q1 | 8.52 Million EUR | -19.45% |
| 2021 Q2 | 5.89 Million EUR | -30.84% |
| 2021 Q3 | -673.87 Thousand EUR | -111.43% |
| 2021 FY | 15.99 Million EUR | -57.62% |
| 2021 Q4 | 1.86 Million EUR | 376.16% |
| 2020 FY | 37.74 Million EUR | -6.9% |
| 2020 Q1 | 9.29 Million EUR | -34.66% |
| 2020 Q4 | 10.58 Million EUR | 9.68% |
| 2020 Q3 | 9.64 Million EUR | -13.18% |
| 2020 Q2 | 11.11 Million EUR | 19.54% |
| 2019 Q2 | 7.88 Million EUR | 4.24% |
| 2019 FY | 40.54 Million EUR | 41.82% |
| 2019 Q1 | 7.56 Million EUR | -49.47% |
| 2019 Q3 | 10.86 Million EUR | 37.71% |
| 2019 Q4 | 14.22 Million EUR | 30.94% |
| 2018 FY | 28.58 Million EUR | 129.8% |
| 2018 Q4 | 14.97 Million EUR | 138.99% |
| 2018 Q3 | 6.26 Million EUR | 93.06% |
| 2018 Q2 | 3.24 Million EUR | -20.87% |
| 2018 Q1 | 4.1 Million EUR | 107.94% |
| 2017 FY | -95.92 Million EUR | -420.12% |
| 2017 Q2 | -28.42 Million EUR | -362.77% |
| 2017 Q3 | -9.7 Million EUR | 65.84% |
| 2017 Q4 | -51.64 Million EUR | -431.97% |
| 2017 Q1 | -6.14 Million EUR | 8.75% |
| 2016 Q3 | -4.22 Million EUR | -15.51% |
| 2016 FY | -18.44 Million EUR | -69.42% |
| 2016 Q1 | -3.83 Million EUR | 9.7% |
| 2016 Q4 | -6.73 Million EUR | -59.48% |
| 2016 Q2 | -3.65 Million EUR | 4.75% |
| 2015 Q2 | -2.47 Million EUR | -71.96% |
| 2015 FY | -10.88 Million EUR | -55.23% |
| 2015 Q1 | -1.43 Million EUR | -108.49% |
| 2015 Q4 | -4.24 Million EUR | -55.82% |
| 2015 Q3 | -2.72 Million EUR | -10.26% |
| 2014 Q1 | -22.05 Million EUR | -278.62% |
| 2014 FY | -7.01 Million EUR | 66.28% |
| 2014 Q4 | 16.93 Million EUR | 379.13% |
| 2014 Q2 | -5.42 Million EUR | 75.39% |
| 2014 Q3 | 3.53 Million EUR | 165.11% |
| 2013 FY | -20.79 Million EUR | 34.73% |
| 2013 Q1 | -6.95 Million EUR | -754.06% |
| 2013 Q2 | -2.42 Million EUR | 65.08% |
| 2013 Q4 | -5.82 Million EUR | -4.26% |
| 2013 Q3 | -5.58 Million EUR | -129.96% |
| 2012 Q3 | -10.08 Million EUR | 18.13% |
| 2012 FY | -31.86 Million EUR | -43.73% |
| 2012 Q1 | -8.65 Million EUR | -113.52% |
| 2012 Q4 | -814.49 Thousand EUR | 91.92% |
| 2012 Q2 | -12.31 Million EUR | -42.36% |
| 2011 Q2 | -6.46 Million EUR | -27.18% |
| 2011 Q3 | -6.57 Million EUR | -1.77% |
| 2011 Q4 | -4.05 Million EUR | 38.38% |
| 2011 FY | -22.16 Million EUR | 70.43% |
| 2011 Q1 | -5.08 Million EUR | 81.73% |
| 2010 FY | -74.96 Million EUR | -63.2% |
| 2010 Q4 | -27.8 Million EUR | -208.27% |
| 2010 Q3 | -9.01 Million EUR | 62.05% |
| 2010 Q2 | -23.76 Million EUR | -129.88% |
| 2010 Q1 | -10.33 Million EUR | 14.52% |
| 2009 Q4 | -12.09 Million EUR | -3.1% |
| 2009 Q3 | -11.73 Million EUR | 9.33% |
| 2009 Q2 | -12.93 Million EUR | -56.94% |
| 2009 Q1 | -8.24 Million EUR | 0.0% |
| 2009 FY | -45.93 Million EUR | -25.92% |
| 2008 FY | -36.47 Million EUR | 29.74% |
| 2007 FY | -51.92 Million EUR | -112.7% |
| 2006 FY | -24.41 Million EUR | -15.41% |
| 2005 FY | -21.15 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 92.795% |
| Alkermes plc | 355.75 Million USD | 102.965% |
| Agenus Inc. | -245.76 Million USD | 95.708% |
| Aptorum Group Limited | -2.82 Million USD | -273.427% |
| Ardelyx, Inc. | -66.06 Million USD | 84.034% |
| Dyadic International, Inc. | -6.79 Million USD | -55.221% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -1026.923% |
| Lantern Pharma Inc. | -15.96 Million USD | 33.916% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 44.568% |
| Novavax, Inc. | -545.06 Million USD | 98.065% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 81.905% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 85.705% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 43.125% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | -5.628% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 82.117% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 97.177% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 56.663% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 71.751% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 93.591% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 85.619% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 48.016% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 83.057% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 67.53% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 92.039% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 97.604% |
| AlloVir, Inc. | -190.41 Million USD | 94.461% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 94.862% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 62.927% |
| Bicycle Therapeutics plc | -180.66 Million USD | 94.162% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 94.109% |
| ChromaDex Corporation | -4.93 Million USD | -113.609% |
| Chimerix, Inc. | -82.09 Million USD | 87.151% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 76.352% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 89.666% |
| CRISPR Therapeutics AG | -153.61 Million USD | 93.133% |
| Precision BioSciences, Inc. | -61.31 Million USD | 82.798% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 93.446% |
| Fortress Biotech, Inc. | -60.63 Million USD | 82.605% |
| Fortress Biotech, Inc. | -60.63 Million USD | 82.605% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 87.07% |
| ImmuCell Corporation | -5.77 Million USD | -82.662% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 90.662% |
| Immix Biopharma, Inc. | -15.42 Million USD | 31.622% |
| Incyte Corporation | 597.59 Million USD | 101.765% |
| Innoviva, Inc. | 179.72 Million USD | 105.869% |
| IO Biotech, Inc. | -86.08 Million USD | 87.747% |
| Jaguar Health, Inc. | -41.3 Million USD | 74.46% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 93.106% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 120.225% |
| ContextLogic Inc. | -317 Million USD | 96.673% |
| MiMedx Group, Inc. | 67.43 Million USD | 115.641% |
| MEI Pharma, Inc. | 17.77 Million USD | 159.332% |
| NextCure, Inc. | -62.72 Million USD | 83.183% |
| Onconetix, Inc. | -37.4 Million USD | 71.804% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 73.282% |
| Opthea Limited | -220.24 Million USD | 95.211% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 79.382% |
| Vaxcyte, Inc. | -402.26 Million USD | 97.378% |
| PDS Biotechnology Corporation | -42.94 Million USD | 75.437% |
| Precigen, Inc. | -95.9 Million USD | 89.002% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 94.768% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 57.022% |
| PureTech Health plc | -65.69 Million USD | 83.944% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 57.961% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 95.03% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 56.663% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 95.909% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 61.275% |
| Acelyrin, Inc. | -381.64 Million USD | 97.236% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -83996.793% |
| Summit Therapeutics Inc. | -614.92 Million USD | 98.285% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 69.068% |
| Senti Biosciences, Inc. | -92.91 Million USD | 88.648% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 89.925% |
| Elevation Oncology, Inc. | -45.7 Million USD | 76.921% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 69.983% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 19.308% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -57.786% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 64.076% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -24.08% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 81.66% |
| Seer, Inc. | -86.27 Million USD | 87.774% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 84.256% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 83.961% |
| ESSA Pharma Inc. | -26.58 Million USD | 60.32% |
| GlycoMimetics, Inc. | -36.89 Million USD | 71.414% |
| GT Biopharma, Inc. | -7.59 Million USD | -38.844% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 95.63% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 79.686% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 114.771% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 80.618% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 78.526% |
| Alzamend Neuro, Inc. | -9.94 Million USD | -6.034% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 98.159% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -193.98% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 79.341% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 95.705% |
| Aptose Biosciences Inc. | -51.2 Million USD | 79.401% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 89.269% |
| Soligenix, Inc. | -6.14 Million USD | -71.771% |
| Century Therapeutics, Inc. | -136.67 Million USD | 92.282% |
| Kura Oncology, Inc. | -152.63 Million USD | 93.089% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 88.177% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | -0.095% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 1965.351% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -1753.779% |
| Autolus Therapeutics plc | -208.38 Million USD | 94.938% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 85.329% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 85.101% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 51.32% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 95.317% |
| GRI Bio, Inc. | -13.03 Million USD | 19.092% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -155.117% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 91.499% |
| IGM Biosciences, Inc. | -246.41 Million USD | 95.719% |
| INmune Bio, Inc. | -30 Million USD | 64.849% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 90.459% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 75.001% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 33.917% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 33.219% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 82.327% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 89.574% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 96.18% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 95.566% |
| Verastem, Inc. | -87.36 Million USD | 87.927% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 80.534% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 93.462% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 90.958% |
| Histogen Inc. | -10.62 Million USD | 0.687% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 26.169% |
| Surrozen, Inc. | -43.04 Million USD | 75.494% |
| Organovo Holdings, Inc. | -14.67 Million USD | 28.103% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -107.351% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 79.847% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 58.247% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 60.843% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | -26.216% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 93.018% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 78.441% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 64.515% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | -1.251% |
| Apollomics, Inc. | -172.6 Million USD | 93.889% |
| Amarin Corporation plc | -59.11 Million USD | 82.156% |
| Mesoblast Limited | -87.95 Million USD | 88.008% |
| Turnstone Biologics Corp. | -55.2 Million USD | 80.891% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 92.823% |
| Synaptogenix, Inc. | -6.03 Million USD | -74.679% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 34.921% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 86.48% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -120.141% |
| Monopar Therapeutics Inc. | -8.4 Million USD | -25.539% |
| Exelixis, Inc. | 207.76 Million USD | 105.077% |
| Better Therapeutics, Inc. | -39.76 Million USD | 73.471% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 92.672% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 98.005% |
| NLS Pharmaceutics AG | -12.17 Million USD | 13.342% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | -35.323% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 65.696% |
| Gritstone bio, Inc. | -138.49 Million USD | 92.384% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 83.638% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -163.703% |
| Avid Bioservices, Inc. | -140.75 Million USD | 92.506% |
| Insmed Incorporated | -749.56 Million USD | 98.593% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 30.557% |
| MediWound Ltd. | -6.71 Million USD | -57.058% |
| OmniAb, Inc. | -50.61 Million USD | 79.162% |
| Alector, Inc. | -130.39 Million USD | 91.91% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 90.725% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 79.656% |
| Zai Lab Limited | -334.62 Million USD | 96.848% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 96.744% |
| Aura Biosciences, Inc. | -76.4 Million USD | 86.195% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 95.504% |
| Immunic, Inc. | -93.61 Million USD | 88.732% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 92.238% |
| Veracyte, Inc. | -74.4 Million USD | 85.823% |
| InMed Pharmaceuticals Inc. | -7.67 Million USD | -37.423% |
| FibroGen, Inc. | -284.23 Million USD | 96.289% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 59.79% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -50.645% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 43.991% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 102.543% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 53.234% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 121.408% |
| TG Therapeutics, Inc. | 12.67 Million USD | 183.239% |
| Galecto, Inc. | -38.34 Million USD | 72.495% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 44.09% |
| Fortrea Holdings Inc. | -3.4 Million USD | -210.235% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 91.671% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 39.418% |
| XBiotech Inc. | -24.55 Million USD | 57.047% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 83.638% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 83.172% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 89.283% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 50.772% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 80.889% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 98.261% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 84.546% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -18426.715% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 95.344% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 52.631% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 95.199% |
| NexImmune, Inc. | -32.34 Million USD | 67.388% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -99.524% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 24.903% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.267% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 56.451% |
| Scopus BioPharma Inc. | -11.6 Million USD | 9.146% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 90.969% |
| Ainos, Inc. | -13.77 Million USD | 23.402% |
| Pluri Inc. | -20.88 Million USD | 49.502% |
| Prothena Corporation plc | -147.02 Million USD | 92.826% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 90.737% |
| Celularity Inc. | -196.29 Million USD | 94.626% |
| Rallybio Corporation | -74.56 Million USD | 85.854% |
| Cue Biopharma, Inc. | -50.73 Million USD | 79.209% |
| MeiraGTx Holdings plc | -84.02 Million USD | 87.447% |
| Omeros Corporation | -117.81 Million USD | 91.047% |
| Humacyte, Inc. | -110.77 Million USD | 90.478% |
| Immunocore Holdings plc | -55.28 Million USD | 80.921% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 41.348% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 54.001% |
| Blueprint Medicines Corporation | -506.98 Million USD | 97.919% |
| CalciMedica, Inc. | -34.35 Million USD | 69.299% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 84.414% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 92.541% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 93.638% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 96.276% |
| Pulmatrix, Inc. | -14.12 Million USD | 25.303% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 70.03% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 87.236% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 97.808% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 89.942% |
| Cytokinetics, Incorporated | -526.24 Million USD | 97.996% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 70.753% |
| Nutriband Inc. | -5.48 Million USD | -92.295% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 73.904% |
| Vor Biopharma Inc. | -117.86 Million USD | 91.051% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 100.243% |
| Evogene Ltd. | -23.87 Million USD | 55.827% |
| ProKidney Corp. | -35.46 Million USD | 70.261% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 91.193% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | -34.448% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 98.36% |
| CorMedix Inc. | -46.33 Million USD | 77.237% |
| BioLineRx Ltd. | -60.61 Million USD | 82.598% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 89.633% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 74.315% |
| Atai Life Sciences N.V. | -40.22 Million USD | 73.777% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 86.921% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 86.033% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 96.39% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 62.161% |
| MediciNova, Inc. | -8.57 Million USD | -23.059% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 91.444% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -25.919% |
| GeoVax Labs, Inc. | -25.96 Million USD | 59.379% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 95.591% |
| Biomea Fusion, Inc. | -117.25 Million USD | 91.004% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 98.317% |
| Mereo BioPharma Group plc | -29.46 Million USD | 64.203% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 93.113% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 94.962% |
| Absci Corporation | -110.56 Million USD | 90.46% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 65.015% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 89.54% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 95.529% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 174.893% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 94.534% |
| Allakos Inc. | -185.7 Million USD | 94.32% |
| Imunon, Inc. | -19.51 Million USD | 45.949% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 89.163% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 109.938% |
| BioAtla, Inc. | -123.46 Million USD | 91.456% |
| NLS Pharmaceutics AG | -12.17 Million USD | 13.342% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 34.395% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 96.777% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 71.453% |
| XOMA Corporation | -40.83 Million USD | 74.167% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 89.646% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 91.1% |
| aTyr Pharma, Inc. | -50.38 Million USD | 79.067% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 87.97% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 93.05% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 95.563% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 69.965% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | -30.352% |
| Akari Therapeutics, Plc | -10 Million USD | -5.396% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -15567.286% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 103.746% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -58.262% |
| UroGen Pharma Ltd. | -102.24 Million USD | 89.684% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 90.123% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -35.627% |
| Orgenesis Inc. | -55.36 Million USD | 80.947% |
| Entera Bio Ltd. | -8.88 Million USD | -18.664% |
| GH Research PLC | -35.58 Million USD | 70.36% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 49.386% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 86.37% |
| Xencor, Inc. | -126.08 Million USD | 91.634% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -180.107% |
| Replimune Group, Inc. | -215.79 Million USD | 95.112% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 50.401% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 520.407% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -58.262% |
| Portage Biotech Inc. | -75.33 Million USD | 85.999% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | -25.919% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 89.087% |
| OncoCyte Corporation | -27.78 Million USD | 62.032% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 21.385% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 5.157% |
| Purple Biotech Ltd. | -19.88 Million USD | 46.942% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -50.278% |
| scPharmaceuticals Inc. | -54.81 Million USD | 80.755% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 39.747% |
| HilleVax, Inc. | -123.56 Million USD | 91.464% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | -4.363% |
| Tharimmune, Inc. | -9.31 Million USD | -13.187% |
| Genprex, Inc. | -30.86 Million USD | 65.82% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 95.529% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 64.95% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -491.919% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -99.169% |
| OKYO Pharma Limited | -16.82 Thousand USD | -62590.708% |
| Savara Inc. | -54.69 Million USD | 80.716% |
| Curis, Inc. | -47.41 Million USD | 77.753% |
| Daré Bioscience, Inc. | -30.16 Million USD | 65.028% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 31.706% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -89.406% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 64.622% |
| BeiGene, Ltd. | -881.7 Million USD | 98.804% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 50.465% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 97.583% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 86.64% |
| Erasca, Inc. | -125.04 Million USD | 91.564% |
| bluebird bio, Inc. | -211.91 Million USD | 95.022% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -110.939% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 106.292% |
| DBV Technologies S.A. | -72.72 Million USD | 85.496% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -110.939% |
| Moderna, Inc. | -4.71 Billion USD | 99.776% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 73.733% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -85.248% |
| Molecular Templates, Inc. | -8.12 Million USD | -29.838% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 82.533% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 90.531% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 92.207% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 77.988% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 92.542% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 94.518% |
| MacroGenics, Inc. | -9.05 Million USD | -16.45% |
| RenovoRx, Inc. | -10.23 Million USD | -3.088% |
| Adicet Bio, Inc. | -142.65 Million USD | 92.606% |
| Prime Medicine, Inc. | -198.13 Million USD | 94.676% |
| Aditxt, Inc. | -32.38 Million USD | 67.425% |
| Adagene Inc. | -18.94 Million USD | 44.327% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -44.261% |
| Quantum-Si incorporated | -95.96 Million USD | 89.008% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 91.138% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 27.643% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 107.971% |
| SciSparc Ltd. | -5.12 Million USD | -105.935% |
| Vericel Corporation | -3.18 Million USD | -231.49% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -8671.434% |
| Minerva Neurosciences, Inc. | -30 Million USD | 64.846% |
| Generation Bio Co. | -126.61 Million USD | 91.669% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 85.529% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 87.206% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 95.976% |
| Invivyd, Inc. | -198.64 Million USD | 94.69% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 96.916% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | -21.429% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 146.251% |
| Artelo Biosciences, Inc. | -9.87 Million USD | -6.826% |
| 2seventy bio, Inc. | -217.57 Million USD | 95.152% |
| ADMA Biologics, Inc. | -28.23 Million USD | 62.647% |
| Clene Inc. | -49.5 Million USD | 78.693% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 52.673% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 78.662% |
| GeoVax Labs, Inc. | -25.96 Million USD | 59.379% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 96.785% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 67.587% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 146.426% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 89.323% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 85.89% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 93.441% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 98.285% |
| Evaxion Biotech A/S | -22.12 Million USD | 52.325% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 86.935% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 94.728% |
| Trevena, Inc. | -40.28 Million USD | 73.819% |
| Surrozen, Inc. | -43.04 Million USD | 75.494% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 84.743% |
| Cingulate Inc. | -23.53 Million USD | 55.182% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -52.604% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 73.537% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | -36.797% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 88.307% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 82.789% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 82.273% |
| Clearmind Medicine Inc. | -11.95 Million USD | 11.769% |
| Kronos Bio, Inc. | -112.67 Million USD | 90.638% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 84.757% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -415792.88% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 87.72% |
| Statera Biopharma, Inc. | -174.4 Million USD | 93.952% |
| ImmunityBio, Inc. | -583.19 Million USD | 98.191% |
| Korro Bio, Inc. | -81.17 Million USD | 87.005% |
| Kineta, Inc. | -14.09 Million USD | 25.186% |
| BioVie Inc. | -32.12 Million USD | 67.161% |
| Codexis, Inc. | -76.24 Million USD | 86.165% |
| Celularity Inc. | -196.29 Million USD | 94.626% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 95.083% |
| Celcuity Inc. | -63.77 Million USD | 83.462% |
| Virax Biolabs Group Limited | -6.73 Million USD | -56.649% |
| Cibus, Inc. | -267.62 Million USD | 96.059% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 73.843% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 70.545% |
| IN8bio, Inc. | -30 Million USD | 64.848% |
| Kodiak Sciences Inc. | -260.49 Million USD | 95.951% |
| Annexon, Inc. | -134.23 Million USD | 92.142% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 90.997% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 82.773% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 66.561% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 97.12% |
| Eyenovia, Inc. | -27.26 Million USD | 61.307% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 148.854% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -1871.589% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 86.194% |
| Arcellx, Inc. | -70.69 Million USD | 85.079% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 74.547% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 92.118% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 64.883% |
| Moolec Science SA | -51.78 Million USD | 79.633% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 79.859% |
| Geron Corporation | -184.12 Million USD | 94.271% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 74.87% |
| Royalty Pharma plc | 1.13 Billion USD | 100.929% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 92.242% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | -18.626% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 50.347% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 93.856% |
| Humacyte, Inc. | -110.77 Million USD | 90.478% |
| Structure Therapeutics Inc. | -89.62 Million USD | 88.23% |
| 89bio, Inc. | -142.18 Million USD | 92.582% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 84.704% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | -1.648% |
| Genelux Corporation | -28.29 Million USD | 62.724% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 63.709% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 94.045% |
| Notable Labs, Ltd. | -11.26 Million USD | 6.357% |
| Liquidia Corporation | -78.5 Million USD | 86.563% |
| Mustang Bio, Inc. | -51.6 Million USD | 79.559% |
| Immunovant, Inc. | -259.33 Million USD | 95.933% |
| Quantum-Si incorporated | -95.96 Million USD | 89.008% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 85.521% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 45.576% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 89.011% |
| Acasti Pharma Inc. | -12.85 Million USD | 17.934% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 53.032% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 33.917% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 94.217% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -145.216% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 15.413% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 64.233% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 72.946% |
| PepGen Inc. | -78.62 Million USD | 86.585% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 64.567% |
| United Therapeutics Corporation | 984.8 Million USD | 101.071% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 52.615% |
| Solid Biosciences Inc. | -96.01 Million USD | 89.014% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -120.141% |
| Immuneering Corporation | -53.47 Million USD | 80.274% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -107.351% |
| Silo Pharma, Inc. | -3.7 Million USD | -185.028% |
| Belite Bio, Inc | -31.63 Million USD | 66.654% |
| XOMA Corporation | -40.83 Million USD | 74.167% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 80.598% |
| Bionomics Limited | -15.49 Billion USD | 99.932% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 87.441% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 63.823% |
| uniQure N.V. | -308.47 Million USD | 96.581% |
| Cassava Sciences, Inc. | -97.21 Million USD | 89.15% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -44.261% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 91.454% |
| Forte Biosciences, Inc. | -31.47 Million USD | 66.489% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | -28.607% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 63.713% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -1871.589% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 59.79% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 36.015% |
| Altimmune, Inc. | -88.44 Million USD | 88.074% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 93.041% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 63.823% |
| Compugen Ltd. | -18.75 Million USD | 43.756% |
| Peak Bio, Inc. | -1259.26 USD | -837534.801% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 77.094% |
| Benitec Biopharma Inc. | -21.75 Million USD | 51.506% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 96.887% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 87.285% |
| Zura Bio Limited | -60.36 Million USD | 82.525% |
| PolyPid Ltd. | -23.86 Million USD | 55.801% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 32.952% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 87.285% |
| Instil Bio, Inc. | -156.08 Million USD | 93.242% |
| argenx SE | -295.05 Million USD | 96.425% |
| Immunome, Inc. | -106.8 Million USD | 90.124% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 75.178% |
| Verona Pharma plc | -54.36 Million USD | 80.599% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 89.443% |
| Shattuck Labs, Inc. | -87.29 Million USD | 87.917% |
| CervoMed Inc. | -2.17 Million USD | -385.664% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 91.538% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 20.787% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 75.782% |
| Moolec Science SA | -51.78 Million USD | 79.633% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -60900.259% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 92.193% |
| AnaptysBio, Inc. | -163.61 Million USD | 93.553% |
| Design Therapeutics, Inc. | -66.86 Million USD | 84.224% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 87.044% |
| NeurAxis, Inc. | -14.62 Million USD | 27.885% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 72.156% |
| Lumos Pharma, Inc. | -34.03 Million USD | 69.007% |
| Achilles Therapeutics plc | -69.66 Million USD | 84.859% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 89.443% |
| 180 Life Sciences Corp. | -19.93 Million USD | 47.088% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 450.573% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -415792.88% |
| Nutriband Inc. | -5.48 Million USD | -92.295% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 89.525% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 78.299% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 86.317% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 68.949% |
| MoonLake Immunotherapeutics | -36 Million USD | 70.706% |
| Palisade Bio, Inc. | -12.3 Million USD | 14.244% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 74.96% |
| Beam Therapeutics Inc. | -132.52 Million USD | 92.041% |
| Neurogene Inc. | -36.31 Million USD | 70.956% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 93.545% |
| AEON Biopharma, Inc. | -52.55 Million USD | 79.93% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 89.253% |
| Sesen Bio, Inc. | -19.88 Million USD | 46.952% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 85.265% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 15.71% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 97.625% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 90.546% |
| Athira Pharma, Inc. | -117.67 Million USD | 91.036% |
| Vaccinex, Inc. | -20.25 Million USD | 47.914% |
| HCW Biologics Inc. | -24.99 Million USD | 57.798% |
| XOMA Corporation | -40.83 Million USD | 74.167% |
| Nektar Therapeutics | -276.05 Million USD | 96.179% |
| Arvinas, Inc. | -367.3 Million USD | 97.128% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -15567.286% |
| Merus N.V. | -154.93 Million USD | 93.192% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 89.174% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 66.392% |
| Rezolute, Inc. | -68.45 Million USD | 84.592% |
| Clene Inc. | -49.5 Million USD | 78.693% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 31.611% |
| BeyondSpring Inc. | -21.02 Million USD | 49.834% |
| Synlogic, Inc. | -57.28 Million USD | 81.586% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 11.369% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 2.568% |
| Peak Bio, Inc. | -1259.26 USD | -837534.801% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 71.773% |
| Krystal Biotech, Inc. | 10.93 Million USD | 196.487% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 92.629% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 96.755% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -128.363% |
| MannKind Corporation | -11.93 Million USD | 11.643% |
| Ikena Oncology, Inc. | -68.16 Million USD | 84.526% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 49.807% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 88.65% |
| Gossamer Bio, Inc. | -179.81 Million USD | 94.134% |
| CohBar, Inc. | -11.96 Million USD | 11.822% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 59.097% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 65.015% |
| Legend Biotech Corporation | -518.25 Million USD | 97.965% |
| Mural Oncology plc | -207.44 Million USD | 94.915% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 91.501% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 42.328% |
| Disc Medicine, Inc. | -76.42 Million USD | 86.199% |
| Champions Oncology, Inc. | -7.27 Million USD | -44.97% |
| REGENXBIO Inc. | -263.49 Million USD | 95.997% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 0.613% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 77.796% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 72.23% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 89.469% |
| Vaxart, Inc. | -82.46 Million USD | 87.209% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 3260.326% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 71.904% |
| Cellectis S.A. | -101.05 Million USD | 89.563% |
| Longeveron Inc. | -21.41 Million USD | 50.74% |
| Repare Therapeutics Inc. | -93.79 Million USD | 88.754% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 98.032% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 85.179% |
| Revolution Medicines, Inc. | -436.36 Million USD | 97.583% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -60.524% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 65.78% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 84.786% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 83.705% |
| Anixa Biosciences, Inc. | -9.81 Million USD | -7.512% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.291% |
| Denali Therapeutics Inc. | -145.22 Million USD | 92.737% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -8671.434% |
| Veru Inc. | -93.15 Million USD | 88.677% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 60.975% |
| Cingulate Inc. | -23.53 Million USD | 55.182% |
| Passage Bio, Inc. | -102.06 Million USD | 89.665% |
| Context Therapeutics Inc. | -23.96 Million USD | 55.984% |
| Exicure, Inc. | -16.91 Million USD | 37.637% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 94.417% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 72.069% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -62.094% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 94.288% |
| Nuvalent, Inc. | -126.21 Million USD | 91.643% |
| ABVC BioPharma, Inc. | -10.51 Million USD | -0.308% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 87.859% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 65.466% |
| OmniAb, Inc. | -50.61 Million USD | 79.162% |
| Anew Medical, Inc. | 1.34 Million USD | 883.583% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 34.26% |
| Lipocine Inc. | -16.35 Million USD | 35.494% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 84.113% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 83.435% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 75.001% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 78.01% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 46.811% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 98.052% |
| Ocugen, Inc. | -63.07 Million USD | 83.278% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 88.982% |
| Q32 Bio Inc. | -112.96 Million USD | 90.662% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 38.646% |
| Alumis Inc. Common Stock | -154.99 Million USD | 93.195% |
| Equillium, Inc. | -13.33 Million USD | 20.9% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 82.527% |
| Coya Therapeutics, Inc. | -7.98 Million USD | -32.051% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 44.046% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 82.147% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 90.79% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 42.605% |
| Dominari Holdings Inc. | -22.88 Million USD | 53.903% |
| Edesa Biotech, Inc. | -8.37 Million USD | -25.955% |
| vTv Therapeutics Inc. | -20.25 Million USD | 47.911% |
| Bio-Techne Corporation | 168.1 Million USD | 106.275% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 97.004% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 108.186% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 91.342% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 72.197% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 90.636% |
| Nkarta, Inc. | -117.5 Million USD | 91.023% |
| BioCardia, Inc. | -11.57 Million USD | 8.841% |
| Iterum Therapeutics plc | -38.37 Million USD | 72.51% |